Abstract
Efficient drug delivery systems (DDSs) can potentially replace with conventional modalities in cancer therapy, like liver cancer. In this study, a novel folic acid (FA)-functionalised and alginate (Alg)-modified poly lactic-co-glycolic acid (PLGA) nanocomposite was developed for delivery of doxorubicin (Dox) to HepG2 and Huh7 liver cancer cells. After synthesising the nanocarrier, several analytical devices, including FT-IR, DLS, TGA, and TEM, were employed for its characterisation. Nano-metric size (55 and 85 nm in diameter), close to neutral surface charge, semi-spherical morphology, and successful synthesis were approved. Dox entrapment efficiency was determined near 1%, and sustained and pH-sensitive drug release behaviours of nanocarrier were ascertained for DDS. Afterwards, the cell viability test was carried out to study the HepG2 and Huh7 cells suppression capability of FA-PLGA-Dox-Alg. About 12% and 10% cell viabilities were observed in HepG2 and Huh7 cancer cells after 24 h treatment with 400 nM concentration of FA-PLGA-Dox-Alg nanocarrier respectively. The IC50 value was observed for 100 nM after 24 h of treatment in cancer cells. These data have indicated that fabricated nanocarrier could be promising DDS against liver cancer and replace with conventional approaches in cancer treatment, like chemotherapy.